THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Clinical trials for THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE trials appear
Sign up with your email to follow new studies for THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could protect unborn babies from dangerous bleeding disorder
Disease control Recruiting nowThis study tests whether a drug called nipocalimab can prevent severe bleeding in unborn babies at risk of FNAIT, a condition where the mother's immune system attacks the baby's platelets. About 50 pregnant women with a history of FNAIT will receive either nipocalimab or standard…
Matched conditions: THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to prevent deadly bleeding in unborn babies
Disease control Recruiting nowThis study tests a medicine called nipocalimab to see if it can lower the risk of severe bleeding or death in unborn babies with a rare condition called FNAIT. The study includes 39 pregnant women who have had a previous pregnancy affected by FNAIT. Participants receive either ni…
Matched conditions: THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC